MZMichelle P. Zeller

Michelle P. Zeller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michelle P. Zeller has a total of 206 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • American Society of Hematology 2026 guidelines for diagnosis of iron deficiency

    by Jacquelyn M. Powers, Ming Y. Lim, Maureen Okam Achebe, Imo J. Akpan, Michael Auerbach, Megan C. Brown, Maria Paula Cardenas, Caroline Cromwell, Thomas DeLoughery, Robert E. Fleming, et al.

    Background: Iron deficiency is the most common micronutrient deficiency and, when untreated, progresses to anemia. Existing guidance on the diagnostic criteria for iron deficiency is limited and not evidence based. Objective: These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about the diagnosis of iron deficiency, taking a global perspective in all settings. Methods: ASH established a multidisciplinary guideline panel that included 1 patient representative and was balanced to minimize potential bias from conflicts of interest. The University of Kansas Health System supported the guideline-development process, including performing systematic evidence reviews on the prevalence of iron deficiency across populations and studies to inform diagnostic thresholds up to July 2025. The panel prioritized clinical questions according to clinical impact and high-risk populations. The panel used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach, including GRADE Evidence-to-Decision frameworks, to assess evidence and make recommendations, which were subsequently open for public comment. Results: The panel agreed on 5 recommendations. Conclusions: Key recommendations of these guidelines include serum ferritin thresholds for specific populations, with the goal to prioritize the diagnosis of iron deficiency, irrespective of the presence of anemia, remarks for considerations of other diagnostic thresholds, and guidance on the diagnosis of iron deficiency in persons with inflammation. Gaps in the literature and research priorities were also identified.


  • Open Access

    Feasibility of a Multidisciplinary IV Iron Pathway for Women with Iron Deficiency Anemia Undergoing Gynaecologic Surgery: The STRONG Pilot Study

    by Sahrish Masood, Megan Watson, Melanie St-John, Maryam Akbari-Moghaddam, Lea Luketic, Mary Coll-Black, Emily Sirotich, Erin Jamula, Christine Wallace, Menaka Pai, et al.

  • Open Access

    Assessment for learning: a realist evaluation of the portfolio in the transfusion medicine area of focused competence program

    by Marissa Laureano, Eric K. Tseng, David Rojas, Ayelet Kuper, Shannon J. Lane, Michelle Zeller

    In Canada, additional training in Transfusion Medicine (TM) can be pursued through Area of Focused Competence (AFC) Diploma programs. The Transfusion Medic

  • Open Access

    Red blood cell transfusion thresholds in acute leukemia: Current practice and physician perspectives from a national survey

    by Dimpy Modi, Brett L. Houston, Brian Leber, Erin Jamula, Nancy Heddle, Chris Hillis, Michelle P. Zeller, Tobias Berg, Donald M. Arnold

    Background: Red blood cell (RBC) transfusions are part of essential supportive therapy in patients with acute leukemia, where patients often present with anemia and thrombocytopenia. Together these cytopenias increase bleeding risk; however, optimal hemoglobin (Hb) thresholds for RBC transfusion remain undefined, and current recommendations for restrictive strategies (<7 g/dL) are based on low‐certainty, indirect evidence. Study Design and Methods: A national web‐based survey was distributed to 43 physicians (24 centers, Canada) to assess current RBC transfusion practice in patients with acute leukemia, perceptions of a liberal threshold (11 g/dL) in the context of a clinical trial, and feasibility considerations. The survey included categorical responses and open‐text fields. Results: Of 38 eligible physicians, 34 responded (89%). For stable, non‐bleeding patients receiving induction chemotherapy, 27/34 (79%) used a Hb threshold of 7 g/dL, 6/34 (18%) used 8 g/dL, and 1/34 (3%) used 9 g/dL. Fourteen (14/34, 41%) respondents indicated that a Hb threshold of 11 g/dL was reasonable for the liberal arm of a clinical trial, while 20/34 (59%) did not. For such a trial, 32/34 (94%) would consider enrolling patients in the trial and 2/34 (6%) would not. Discussion: A Hb threshold of 7 g/dL was most reported as standard‐of‐care. Most respondents supported enrolling their patients in a clinical trial comparing a liberal RBC transfusion strategy of 11 g/dL with standard‐of‐care. The feasibility of 11 g/dL should be tested with clear justification, appropriate study outcomes, and attention to safety risks and resource demands.


  • Open Access

    Perioperative iron therapy for women undergoing gynecologic procedures: a systematic review and meta-analysis

    by Beth MacLean, Jayne Lim, Emily Sirotich, Saifur R. Chowdhury, Megan Watson, Menaka Pai, Nadia Gabarin, Bram Rochwerg, Leah Luketic, Yang Liu, et al.

  • Open Access

    Exploring the immunomodulatory impacts of blood manufacturing consolidation

    by Amanda Kauffman, Michelle P. Zeller, Yang Liu, Jason P. Acker, Donald M. Arnold, Nancy Heddle, Chris Hillis, Na Li, Bram Rochwerg, Kayla Lucier, et al.

    Introduction: The immunomodulatory consequences of blood transfusion, known as transfusion‐related immune modulation (TRIM), are often not captured by hemovigilance systems. Changes to blood product manufacturing processes may impact patient outcomes. Design and Methods: We conducted a retrospective study of hospitalized adults (≥18 years) in Hamilton, ON, who received ≥1 red blood cell (RBC) transfusion(s) between 2010 and 2014. Primary outcome was in hospital mortality; TRIM outcomes included respiratory failure, organ dysfunction, and sepsis. We evaluated outcomes before and after the change made by Canadian Blood Services (2012) to consolidate manufacturing of blood products in Ontario. Exclusions included autologous, washed, or deglycerolized RBC transfusions, RBCs manufactured outside select regional sites, or patients who received both pre‐/post‐consolidation RBCs. Data was obtained from the TRUST database. Logistic regression adjusted for key covariates. Results: A total of 9871 pre‐ and 7871 post‐consolidation patients met inclusion criteria. Multivariate analysis demonstrated no change in in‐hospital mortality (odds ratio [OR] 1.00, 95% confidence interval [CI] 0.89–1.14, p = 0.95), respiratory failure (OR 0.83, CI 0.65–1.06, p = 0.14) or organ dysfunction (OR 0.95, 95% CI 0.84–1.08, p = 0.42) comparing post to pre‐consolidation. However, hospital‐onset sepsis was lower post‐consolidation (OR 0.59, 95% CI 0.48–0.73, p < 0.001). Conclusions: Consolidation of blood production in Ontario was not associated with changes in rates of in‐hospital mortality, respiratory failure, or organ dysfunction among transfusion recipients, but may be associated with a lower risk of sepsis. TRIM and the clinical impacts of changes to blood processing require further study.

  • Learning From Clinical Supervisor Practice Variability: Exploring Medical Resident and Fellow Experiences and Interpretations

    by Siraj Md Mithoowani, Shahzaib Hbsc Khattak, Susan Ma Lieberman, Eric K. MD Tseng, Michelle P. Md Zeller, Jeroen van Merriënboer

    Purpose: Clinical practice variability is characterized by 2 or more clinicians making different treatment decisions despite encountering a similar case. This study explores how medical residents and fellows experience and interpret intersupervisor clinical practice variability and how these variations influence learning. Method: Seventeen senior residents or fellows in internal medicine, hematology, or thrombosis medicine (postgraduate year 3 or above) participated in semistructured interviews after a clinical rotation in thrombosis medicine from December 2019 to March 2021. Data collection and analysis occurred iteratively and concurrently in a manner consistent with constructivist grounded theory. Variation theory was used to guide the development of some interview questions. A central tenet of this theory is that learning occurs by experiencing 3 sequential patterns of variation: contrast, generalization, and fusion. Participants were recruited purposively with respect to specialty until theoretical sufficiency was reached. Results: Clinical practice variability was experienced by all participants. Residents and fellows attributed practice variability to intrinsic differences among supervisors; interinstitutional differences; selection and interpretation of evidence; patient preferences, priorities, and fears; and their own participation in the decision-making process. Clinical practice variability helped residents and fellows discern key features of cases that influenced decision-making (contrast), group similar cases so that the appropriate evidence could be applied (generalization), and develop attitudes consistent with providing individualized patient care (fusion). Observing practice variability was more helpful for fifth- and sixth-year residents and less helpful for third- and fourth-year residents. Conclusions: Clinical practice variability helped residents and fellows discern critical aspects, group similar patients, and practice individualized medicine. Future research should characterize how clinical practice variability influences learning across the spectrum of training, how supervisors could encourage learning from practice variability, and how curricula could be modified to allow learners greater opportunity to reflect on and consolidate the practice differences they observe.


  • Optimizing Informed Consent Discussions: Developing a Narrative for Transfusion Consent

    by Michelle P. Zeller, Marissa Laureano, Aditi Khandelwal, Shannon J. Lane, Richard Haspel, Mark Fung


  • Open Access

    Impact of iron supplementation on patient outcomes for women with abnormal uterine bleeding: a protocol for a systematic review and meta-analysis

    by Hasmik Nazaryan, Megan Watson, Dana Ellingham, Swarni Thakar, Andrea Wang, Menaka Pai, Yang Liu, Bram Rochwerg, Nadia Gabarin, Donald Arnold, et al.

    Background: Abnormal uterine bleeding (AUB), which includes heavy menstrual bleeding (HMB), is a common condition placing women at increased risk for developing iron deficiency and iron deficiency anemia (IDA). Depletion of iron stores has negative implications on physical, social, and emotional health, as well as quality of life. Iron supplements are safe, effective, and readily available, while red blood cell (RBC) transfusions have inherent risks including infectious and immune reactions. Despite high prevalence of IDA among women with AUB, there are limited studies on the impact of iron therapies on patient outcomes. This systematic review and meta-analysis will evaluate the impact of iron supplementation on patient outcomes for women with AUB, when compared to combination therapy, no intervention, placebo, or standard of care. Methods: We will conduct a systematic review and meta-analysis of randomized controlled trials and observational studies evaluating the impact of iron interventions on patient outcomes for women with AUB. Systematic literature searches will be conducted in major databases including MEDLINE, EMBASE, CENTRAL, CINAHL, and Web of Science. Studies assessing the impact of iron interventions on patient outcomes in women experiencing AUB, in comparison to combination therapy, no intervention, placebo, or standard of care, will be included in the review. Independent reviewers will screen for eligibility, assess risk of bias, and abstract data. Overall certainty of evidence for each outcome will be assessed using the GRADE approach. We will meta-analyze outcomes which are sufficiently homogeneous to summarize intervention effects and narratively synthesize nonhomogeneous outcomes. The main outcomes of interest are hemoglobin levels immediately prior to surgery and post-operatively, number of RBC transfusions, and adverse effects. Secondary outcomes will include length of hospital stay, intraoperative blood loss, adverse and side effects, quality of life, and iron indices. Discussion: This review will evaluate the impact of iron interventions on patient outcomes in women with IDA secondary to AUB with focus on changes in hematological and iron indices, red blood cell utilization, quality of life, cost of treatment, and adverse events. The results will inform evidence-based clinical practice for the management of iron deficiency and IDA secondary to AUB. Systematic review registration: PROSPERO CRD42019137282.